Sunday, October 26, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Mixed Signals for NetScout Investors

Dieter Jaworski by Dieter Jaworski
October 26, 2025
in Analysis, Cyber Security, Insider Trading, Tech & Software
0
NetScout Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Investors in NetScout are facing a complex puzzle as major financial institutions and corporate insiders move in opposite directions. The stock concluded Friday’s trading session at $26.85, marking a 1.40 percent gain amid fluctuating prices throughout the day.

Corporate Insiders Reduce Holdings

While institutional players demonstrate confidence, a different story unfolds behind the scenes. Director Michael Szabados decreased his stake by 9.32 percent, while Alfred Grasso executed an even larger reduction of 14.61 percent. Collectively, insiders have disposed of shares worth $358,873 over the past three months, raising questions about their outlook for the network security company.

Heavyweight Investors Build Positions

The substantial institutional ownership of 91.64 percent underscores strong support from major investment firms. Recent regulatory filings reveal significant position building: Allspring Global Investments added 22,004 shares during the second quarter of 2025, while CWM LLC dramatically expanded its exposure with a 91.1 percent increase. These moves represent a powerful endorsement from sophisticated market participants.

Should investors sell immediately? Or is it worth buying NetScout?

Divided Analyst Outlook Ahead of Earnings

Market experts display considerable disagreement in their assessment of NetScout’s prospects. The consensus recommendation currently stands at “Hold” with a $29 price target, yet individual firms present contrasting views. B. Riley maintains a “Buy” rating with a more optimistic $33 target, while Weiss Ratings advocates selling the security.

All eyes now turn to the company’s quarterly results scheduled for November 6. The upcoming financial report will reveal whether the institutional buyers or the departing insiders made the wiser strategic decision.

Ad

NetScout Stock: Buy or Sell?! New NetScout Analysis from October 26 delivers the answer:

The latest NetScout figures speak for themselves: Urgent action needed for NetScout investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 26.

NetScout: Buy or sell? Read more here...

Tags: NetScout
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Arcus Biosciences Stock
Analysis

Biotech Analyst Battle: Arcus Biosciences Faces Conflicting Outlooks

October 26, 2025
Xeris Pharmaceuticals Stock
Analysis

Xeris Pharmaceuticals Shares Extend Rally to Fresh Peak

October 26, 2025
Hims & Hers Health Registered (A) Stock
Earnings

Hims & Hers Stock Plunge: A Perfect Storm of Insider Selling and Leadership Shifts

October 26, 2025
Next Post
Caleres Stock

Caleres Shares Face Mounting Pressure as Analyst Concerns Deepen

Workiva Stock

Workiva Shares: Conflicting Signals Create Investor Dilemma

Arbor Realty Stock

Critical Earnings Report Looms for Arbor Realty Trust

Recommended

Axsome Stock

Axsome Therapeutics Emerges as a High-Growth Contender in Neurological Drug Development

2 months ago
Super Micro Computer Stock

Super Micro Computer Faces Profitability Crisis as Margins Contract

2 months ago
Cisco Stock

Cisco Stock: Solid Earnings Fail to Impress Amid AI Hype

2 months ago
Films and camera

HCA Healthcare Reports Impressive Financial Results and Optimistic Outlook for 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Hims & Hers Stock Plunge: A Perfect Storm of Insider Selling and Leadership Shifts

Pfizer Secures Key Regulatory Wins Amid Ongoing Legal Challenges

Porsche’s Corporate Overhaul Faces Billion-Euro Hurdles

Harmony Biosciences Shares Surge on Blockbuster Drug Performance

Two EV Trailblazers: Assessing Rivian and Lucid’s Divergent Paths

The Chefs’ Warehouse Faces Critical Earnings Test This Week

Trending

Arcus Biosciences Stock
Analysis

Biotech Analyst Battle: Arcus Biosciences Faces Conflicting Outlooks

by Andreas Sommer
October 26, 2025
0

Arcus Biosciences finds itself at the center of a sharp Wall Street divide. The biopharmaceutical company is...

Xeris Pharmaceuticals Stock

Xeris Pharmaceuticals Shares Extend Rally to Fresh Peak

October 26, 2025
HNI Stock

HNI Shares Face Pivotal Week with Earnings and Acquisition Finale

October 26, 2025
Hims & Hers Health Registered (A) Stock

Hims & Hers Stock Plunge: A Perfect Storm of Insider Selling and Leadership Shifts

October 26, 2025
Pfizer Stock

Pfizer Secures Key Regulatory Wins Amid Ongoing Legal Challenges

October 26, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Biotech Analyst Battle: Arcus Biosciences Faces Conflicting Outlooks
  • Xeris Pharmaceuticals Shares Extend Rally to Fresh Peak
  • HNI Shares Face Pivotal Week with Earnings and Acquisition Finale

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com